ユーイング肉腫治療の世界市場 2024-2028

概要

ユーイング肉腫治療市場は2023-2028年に2億509万米ドル、予測期間中のCAGRは6.26%で成長すると予測されます。

当レポートでは、ユーイング肉腫治療市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。この市場を牽引しているのは、ユーイング肉腫に対する認知度の向上と資金提供、ユーイング肉腫治療に対する規制上の優遇措置、財政支援プログラムや償還制度などです。

当レポートでは、今後数年間のユーイング肉腫治療市場成長を牽引する主な理由の1つとして再生療法の出現を挙げています。また、CRISPR-cas9技術の出現と強力な研究助成金が市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 世界のユーイング肉腫治療市場 2018-2022
• エンドユーザー別セグメント分析 2018-2022
• タイプ別セグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：エンドユーザー別

• 市場セグメント
• 比較：エンドユーザー別
• 病院：市場規模と予測 2023-2028
• 専門クリニック：市場規模と予測 2023-2028
• その他：市場規模と予測 2023-2028
• 市場機会：エンドユーザー別

第7章 市場セグメンテーション：タイプ別

• 市場セグメント
• 比較：タイプ別
• 併用療法：市場規模と予測 2023-2028
• 単独療法：市場規模と予測 2023-2028
• 市場機会：タイプ別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• カナダ：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 日本：市場規模と予測 2023-2028
• 市場機会：地域別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Advantech Co. Ltd.
• Amneal Pharmaceuticals Inc.
• Baxter International Inc.
• Bristol Myers Squibb Co.
• Cellectar Biosciences Inc.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• Fresenius Kabi AG
• GlaxoSmithKline Plc
• Gradalis Inc.
• Johnson and Johnson
• Novartis AG
• Ocean pharmaceutical
• Pfizer Inc.
• PharmaMar SA

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market by Geography
• Exhibits5: Executive Summary - Chart on Market Segmentation by End-user
• Exhibits6: Executive Summary - Chart on Market Segmentation by Type
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global ewings sarcoma treatment market 2018 - 2022 ($ million)
• Exhibits19: Historic Market Size - End-user Segment 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on End-user - Market share 2023-2028 (%)
• Exhibits31: Data Table on End-user - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by End-user
• Exhibits33: Data Table on Comparison by End-user
• Exhibits34: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Specialty clinics - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on Specialty clinics - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on Specialty clinics - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Specialty clinics - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits44: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Others - Year-over-year growth 2023-2028 (%)
• Exhibits46: Market opportunity by End-user ($ million)
• Exhibits47: Data Table on Market opportunity by End-user ($ million)
• Exhibits48: Chart on Type - Market share 2023-2028 (%)
• Exhibits49: Data Table on Type - Market share 2023-2028 (%)
• Exhibits50: Chart on Comparison by Type
• Exhibits51: Data Table on Comparison by Type
• Exhibits52: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
• Exhibits53: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
• Exhibits54: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
• Exhibits57: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
• Exhibits60: Market opportunity by Type ($ million)
• Exhibits61: Data Table on Market opportunity by Type ($ million)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share by geography 2023-2028 (%)
• Exhibits64: Data Table on Market share by geography 2023-2028 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits89: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits101: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits103: Market opportunity by geography ($ million)
• Exhibits104: Data Tables on Market opportunity by geography ($ million)
• Exhibits105: Impact of drivers and challenges in 2023 and 2028
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: Advantech Co. Ltd. - Overview
• Exhibits112: Advantech Co. Ltd. - Business segments
• Exhibits113: Advantech Co. Ltd. - Key offerings
• Exhibits114: Advantech Co. Ltd. - Segment focus
• Exhibits115: Amneal Pharmaceuticals Inc. - Overview
• Exhibits116: Amneal Pharmaceuticals Inc. - Business segments
• Exhibits117: Amneal Pharmaceuticals Inc. - Key news
• Exhibits118: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibits119: Amneal Pharmaceuticals Inc. - Segment focus
• Exhibits120: Baxter International Inc. - Overview
• Exhibits121: Baxter International Inc. - Business segments
• Exhibits122: Baxter International Inc. - Key news
• Exhibits123: Baxter International Inc. - Key offerings
• Exhibits124: Baxter International Inc. - Segment focus
• Exhibits125: Bristol Myers Squibb Co. - Overview
• Exhibits126: Bristol Myers Squibb Co. - Product / Service
• Exhibits127: Bristol Myers Squibb Co. - Key news
• Exhibits128: Bristol Myers Squibb Co. - Key offerings
• Exhibits129: Cellectar Biosciences Inc. - Overview
• Exhibits130: Cellectar Biosciences Inc. - Product / Service
• Exhibits131: Cellectar Biosciences Inc. - Key offerings
• Exhibits132: Daiichi Sankyo Co. Ltd. - Overview
• Exhibits133: Daiichi Sankyo Co. Ltd. - Product / Service
• Exhibits134: Daiichi Sankyo Co. Ltd. - Key news
• Exhibits135: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibits136: Eli Lilly and Co. - Overview
• Exhibits137: Eli Lilly and Co. - Product / Service
• Exhibits138: Eli Lilly and Co. - Key news
• Exhibits139: Eli Lilly and Co. - Key offerings
• Exhibits140: Fresenius Kabi AG - Overview
• Exhibits141: Fresenius Kabi AG - Business segments
• Exhibits142: Fresenius Kabi AG - Key news
• Exhibits143: Fresenius Kabi AG - Key offerings
• Exhibits144: Fresenius Kabi AG - Segment focus
• Exhibits145: GlaxoSmithKline Plc - Overview
• Exhibits146: GlaxoSmithKline Plc - Business segments
• Exhibits147: GlaxoSmithKline Plc - Key news
• Exhibits148: GlaxoSmithKline Plc - Key offerings
• Exhibits149: GlaxoSmithKline Plc - Segment focus
• Exhibits150: Gradalis Inc. - Overview
• Exhibits151: Gradalis Inc. - Product / Service
• Exhibits152: Gradalis Inc. - Key offerings
• Exhibits153: Johnson and Johnson - Overview
• Exhibits154: Johnson and Johnson - Business segments
• Exhibits155: Johnson and Johnson - Key news
• Exhibits156: Johnson and Johnson - Key offerings
• Exhibits157: Johnson and Johnson - Segment focus
• Exhibits158: Novartis AG - Overview
• Exhibits159: Novartis AG - Business segments
• Exhibits160: Novartis AG - Key offerings
• Exhibits161: Novartis AG - Segment focus
• Exhibits162: Ocean pharmaceutical - Overview
• Exhibits163: Ocean pharmaceutical - Product / Service
• Exhibits164: Ocean pharmaceutical - Key offerings
• Exhibits165: Pfizer Inc. - Overview
• Exhibits166: Pfizer Inc. - Product / Service
• Exhibits167: Pfizer Inc. - Key news
• Exhibits168: Pfizer Inc. - Key offerings
• Exhibits169: PharmaMar SA - Overview
• Exhibits170: PharmaMar SA - Business segments
• Exhibits171: PharmaMar SA - Key offerings
• Exhibits172: PharmaMar SA - Segment focus
• Exhibits173: Inclusions checklist
• Exhibits174: Exclusions checklist
• Exhibits175: Currency conversion rates for US$
• Exhibits176: Research methodology
• Exhibits177: Validation techniques employed for market sizing
• Exhibits178: Information sources
• Exhibits179: List of abbreviations

Abstract

The Ewing's sarcoma treatment market is forecasted to grow by USD 205.09 mn during 2023-2028, accelerating at a CAGR of 6.26% during the forecast period. The report on the Ewing's sarcoma treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing awareness about and funding for Ewings sarcoma, regulatory incentives for Ewing's sarcoma treatment, and financial assistance programs and reimbursement schemes.

Technavio's Ewing's sarcoma treatment market is segmented as below:

By End-user

• Hospitals
• Specialty clinics
• Others

By Type

• Combination therapy
• Monotherapy

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the emergence of regenerative therapies as one of the prime reasons driving the Ewing's sarcoma treatment market growth during the next few years. Also, the advent of CRISPR-cas9 technology and strong research grants will lead to sizable demand in the market.

The report on the Ewing's sarcoma treatment market covers the following areas:

• Ewing's sarcoma treatment market sizing
• Ewing's sarcoma treatment market forecast
• Ewing's sarcoma treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Ewing's sarcoma treatment market vendors including Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, and UPMC Hillman Cancer Center. Also, the Ewing's sarcoma treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market by Geography
• Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global Ewings sarcoma treatment market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global ewings sarcoma treatment market 2018 - 2022 ($ million)
• 4.2 End-user Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - End-user Segment 2018 - 2022 ($ million)
• 4.3 Type Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by End-user

• 6.1 Market segments
• Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
• Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
• 6.2 Comparison by End-user
• Exhibit 32: Chart on Comparison by End-user
• Exhibit 33: Data Table on Comparison by End-user
• 6.3 Hospitals - Market size and forecast 2023-2028
• Exhibit 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
• 6.4 Specialty clinics - Market size and forecast 2023-2028
• Exhibit 38: Chart on Specialty clinics - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Specialty clinics - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Specialty clinics - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Specialty clinics - Year-over-year growth 2023-2028 (%)
• 6.5 Others - Market size and forecast 2023-2028
• Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by End-user
• Exhibit 46: Market opportunity by End-user ($ million)
• Exhibit 47: Data Table on Market opportunity by End-user ($ million)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 48: Chart on Type - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
• 7.2 Comparison by Type
• Exhibit 50: Chart on Comparison by Type
• Exhibit 51: Data Table on Comparison by Type
• 7.3 Combination therapy - Market size and forecast 2023-2028
• Exhibit 52: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
• 7.4 Monotherapy - Market size and forecast 2023-2028
• Exhibit 56: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
• 7.5 Market opportunity by Type
• Exhibit 60: Market opportunity by Type ($ million)
• Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share by geography 2023-2028 (%)
• Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Canada - Market size and forecast 2023-2028
• Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.11 Japan - Market size and forecast 2023-2028
• Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity by geography
• Exhibit 103: Market opportunity by geography ($ million)
• Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Advantech Co. Ltd.
• Exhibit 111: Advantech Co. Ltd. - Overview
• Exhibit 112: Advantech Co. Ltd. - Business segments
• Exhibit 113: Advantech Co. Ltd. - Key offerings
• Exhibit 114: Advantech Co. Ltd. - Segment focus
• 12.4 Amneal Pharmaceuticals Inc.
• Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus
• 12.5 Baxter International Inc.
• Exhibit 120: Baxter International Inc. - Overview
• Exhibit 121: Baxter International Inc. - Business segments
• Exhibit 122: Baxter International Inc. - Key news
• Exhibit 123: Baxter International Inc. - Key offerings
• Exhibit 124: Baxter International Inc. - Segment focus
• 12.6 Bristol Myers Squibb Co.
• Exhibit 125: Bristol Myers Squibb Co. - Overview
• Exhibit 126: Bristol Myers Squibb Co. - Product / Service
• Exhibit 127: Bristol Myers Squibb Co. - Key news
• Exhibit 128: Bristol Myers Squibb Co. - Key offerings
• 12.7 Cellectar Biosciences Inc.
• Exhibit 129: Cellectar Biosciences Inc. - Overview
• Exhibit 130: Cellectar Biosciences Inc. - Product / Service
• Exhibit 131: Cellectar Biosciences Inc. - Key offerings
• 12.8 Daiichi Sankyo Co. Ltd.
• Exhibit 132: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 133: Daiichi Sankyo Co. Ltd. - Product / Service
• Exhibit 134: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 135: Daiichi Sankyo Co. Ltd. - Key offerings
• 12.9 Eli Lilly and Co.
• Exhibit 136: Eli Lilly and Co. - Overview
• Exhibit 137: Eli Lilly and Co. - Product / Service
• Exhibit 138: Eli Lilly and Co. - Key news
• Exhibit 139: Eli Lilly and Co. - Key offerings
• 12.10 Fresenius Kabi AG
• Exhibit 140: Fresenius Kabi AG - Overview
• Exhibit 141: Fresenius Kabi AG - Business segments
• Exhibit 142: Fresenius Kabi AG - Key news
• Exhibit 143: Fresenius Kabi AG - Key offerings
• Exhibit 144: Fresenius Kabi AG - Segment focus
• 12.11 GlaxoSmithKline Plc
• Exhibit 145: GlaxoSmithKline Plc - Overview
• Exhibit 146: GlaxoSmithKline Plc - Business segments
• Exhibit 147: GlaxoSmithKline Plc - Key news
• Exhibit 148: GlaxoSmithKline Plc - Key offerings
• Exhibit 149: GlaxoSmithKline Plc - Segment focus
• 12.12 Gradalis Inc.
• Exhibit 150: Gradalis Inc. - Overview
• Exhibit 151: Gradalis Inc. - Product / Service
• Exhibit 152: Gradalis Inc. - Key offerings
• 12.13 Johnson and Johnson
• Exhibit 153: Johnson and Johnson - Overview
• Exhibit 154: Johnson and Johnson - Business segments
• Exhibit 155: Johnson and Johnson - Key news
• Exhibit 156: Johnson and Johnson - Key offerings
• Exhibit 157: Johnson and Johnson - Segment focus
• 12.14 Novartis AG
• Exhibit 158: Novartis AG - Overview
• Exhibit 159: Novartis AG - Business segments
• Exhibit 160: Novartis AG - Key offerings
• Exhibit 161: Novartis AG - Segment focus
• 12.15 Ocean pharmaceutical
• Exhibit 162: Ocean pharmaceutical - Overview
• Exhibit 163: Ocean pharmaceutical - Product / Service
• Exhibit 164: Ocean pharmaceutical - Key offerings
• 12.16 Pfizer Inc.
• Exhibit 165: Pfizer Inc. - Overview
• Exhibit 166: Pfizer Inc. - Product / Service
• Exhibit 167: Pfizer Inc. - Key news
• Exhibit 168: Pfizer Inc. - Key offerings
• 12.17 PharmaMar SA
• Exhibit 169: PharmaMar SA - Overview
• Exhibit 170: PharmaMar SA - Business segments
• Exhibit 171: PharmaMar SA - Key offerings
• Exhibit 172: PharmaMar SA - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 173: Inclusions checklist
• Exhibit 174: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 175: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 176: Research methodology
• Exhibit 177: Validation techniques employed for market sizing
• Exhibit 178: Information sources
• 13.5 List of abbreviations
• Exhibit 179: List of abbreviations